Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy.
Herpes simplex virus (HSV) is a naturally occurring double-stranded DNA virus that has been adapted into an efficient vector for in vivo gene transfer. HSV-based vectors exhibit wide tropism, large transgene size capacity, and moderately prolonged transgene expression profiles. Clinical implementation of HSV vector-based gene therapy for prevention and/or amelioration of human diseases eventually will be realized, but inherently this goal presents a series of significant challenges, one of which relates to issues of immune system involvement. Few experimental reports have detailed HSV vector-engendered immune responses and subsequent resolution events primarily within the confines of the central nervous system. Herein, we describe the immunobiology of HSV and its derived vector platforms, thus providing an initiation point from where to propose requisite experimental investigation and potential approaches to prevent and/or counter adverse antivector immune responses.
Bowers
W J
WJ
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA.Rochester, NY 14642, USA.
Olschowka
J A
JA
Federoff
H J
HJ
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D002490:Central Nervous System / Q000276:immunology* / Q000821:virology*; D003169:Complement Inactivator Proteins / Q000276:immunology; D005818:Genetic Engineering / Q000379:methods; D015316:Genetic Therapy / Q000009:adverse effects*; D005822:Genetic Vectors / Q000276:immunology*; D018259:Herpesvirus 1, Human / Q000276:immunology*; D006801:Humans; D011994:Recombinant Proteins / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology; D014777:Virus Diseases / Q000276:immunology*; D014779:Virus Replication / Q000502:physiology
D000914:Antibodies, Viral; D003169:Complement Inactivator Proteins; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins